A real- world single center study to assess effect of Second-Generation Novel Agents on Overall Survival of Early Salvage Treatment to relapsed refractory multiple myeloma

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 22 Jul 2020

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Bortezomib (Primary) ; Carfilzomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Ixazomib (Primary) ; Lenalidomide (Primary) ; Pomalidomide (Primary)
Indications Multiple myeloma
Focus Therapeutic Use

22 Jul 2020 New trial record
21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com